Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial
| Autor: | Samuel D. Moscavitch, Kaspar Broch, Sigrun Halvorsen, Lars Gullestad, Marius Trøseid, Christiane Caroline Mayerhofer, Andrea De Lorenzo, Pål Aukrust, Ingebjørg Seljeflot, Anders Hovland, Johannes R. Hov, Knut Tore Lappegård, Ayodeji Awoyemi |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cardiac function curve
medicine.medical_specialty 030204 cardiovascular system & hematology Gut flora Gastroenterology law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Internal medicine medicine Clinical endpoint 030212 general & internal medicine Ejection fraction biology business.industry medicine.disease biology.organism_classification Rifaximin chemistry Heart failure Cardiology and Cardiovascular Medicine business Saccharomyces boulardii |
| Zdroj: | ESC Heart Failure. 5:977-984 |
| ISSN: | 2055-5822 |
| Popis: | AIMS Heart failure (HF) is a multifactorial disease. Current treatments target only a fraction of the putative pathophysiological pathways. In patients with HF, reduced cardiac output and congestion cause increased gut wall permeability. It has been suggested that leakage of microbial products is detrimental to the heart, at least partly through activation of systemic inflammatory pathways, which again could promote gut leakage. Whether manipulating the gut microbiota can improve cardiac function in patients with HF remains unknown. We aim to evaluate the effect of drugs targeting the gut microbiota on left ventricular function, quality of life, and functional capacity, as well as on markers of gut leakage and inflammation, in stable patients with HF with reduced ejection fraction. METHODS AND RESULTS GutHeart is a randomized, open-label, controlled trial. Four centres will randomize 150 patients with stable HF and a left ventricular ejection fraction |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text